Cargando…
NTBI levels in C282Y homozygotes after therapeutic phlebotomy
C282Y homozygotes exposed to sustained elevated transferrin saturation (TS) may develop worsening clinical symptoms. This might be related to the appearance of non‐transferrin bound iron (NTBI) when TS≥50% and labile plasma iron (LPI) when TS levels reach 75–80%. In this study, NTBI levels were exam...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9422009/ https://www.ncbi.nlm.nih.gov/pubmed/36051052 http://dx.doi.org/10.1002/jha2.507 |
_version_ | 1784777723452850176 |
---|---|
author | Ryan, Eleanor Mulready, Keith Wiegerinck, Erwin Russell, Jennifer Swinkels, Dorine W. Stewart, Stephen |
author_facet | Ryan, Eleanor Mulready, Keith Wiegerinck, Erwin Russell, Jennifer Swinkels, Dorine W. Stewart, Stephen |
author_sort | Ryan, Eleanor |
collection | PubMed |
description | C282Y homozygotes exposed to sustained elevated transferrin saturation (TS) may develop worsening clinical symptoms. This might be related to the appearance of non‐transferrin bound iron (NTBI) when TS≥50% and labile plasma iron (LPI) when TS levels reach 75–80%. In this study, NTBI levels were examined in 219 randomly selected untreated and treated C282Y homozygotes. Overall, 161 of 219 had TS ≥ 50%, 124 of whom had detectable NTBI (≥0.47 µM, 1.81 µM [0.92–2.46 µM]) with a median serum ferritin 320 µg/L (226–442 µg/L). Ninety of 219 homozygotes had TS ≥ 75%, and all had detectable NTBI (2.21 µM [1.53–2.59 µM] with a median ferritin 338 µg/L [230–447 µg/L]). Of 125 homozygotes who last had phlebotomy ≥12 months ago (42 months [25–74 months], 92 had TS levels ≥ 50%, and 70 of these had NTBI ≥ 0.47 µM (2.06 µM [1.23–2.61µM]). Twenty‐six of these 70 had a normal ferritin. Fifty‐five of 125 had TS ≥ 75%, and NTBI was detected in all of these (2.32 µM [1.57–2.77 µM]) with a median ferritin 344 µg/L (255–418 µg/L). Eighteen of these 55 had a normal ferritin. In summary, NTBI is frequently found in C282Y homozygotes with TS ≥ 50%. Furthermore, C282Y homozygotes in the maintenance phase often have TS ≥ 50% together with a normal ferritin. Therefore, monitoring the TS level during the maintenance phase is recommended as an accessible clinical marker of the presence of NTBI. |
format | Online Article Text |
id | pubmed-9422009 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-94220092022-08-31 NTBI levels in C282Y homozygotes after therapeutic phlebotomy Ryan, Eleanor Mulready, Keith Wiegerinck, Erwin Russell, Jennifer Swinkels, Dorine W. Stewart, Stephen EJHaem Sickle Cell, Thrombosis, and Benign Haematology C282Y homozygotes exposed to sustained elevated transferrin saturation (TS) may develop worsening clinical symptoms. This might be related to the appearance of non‐transferrin bound iron (NTBI) when TS≥50% and labile plasma iron (LPI) when TS levels reach 75–80%. In this study, NTBI levels were examined in 219 randomly selected untreated and treated C282Y homozygotes. Overall, 161 of 219 had TS ≥ 50%, 124 of whom had detectable NTBI (≥0.47 µM, 1.81 µM [0.92–2.46 µM]) with a median serum ferritin 320 µg/L (226–442 µg/L). Ninety of 219 homozygotes had TS ≥ 75%, and all had detectable NTBI (2.21 µM [1.53–2.59 µM] with a median ferritin 338 µg/L [230–447 µg/L]). Of 125 homozygotes who last had phlebotomy ≥12 months ago (42 months [25–74 months], 92 had TS levels ≥ 50%, and 70 of these had NTBI ≥ 0.47 µM (2.06 µM [1.23–2.61µM]). Twenty‐six of these 70 had a normal ferritin. Fifty‐five of 125 had TS ≥ 75%, and NTBI was detected in all of these (2.32 µM [1.57–2.77 µM]) with a median ferritin 344 µg/L (255–418 µg/L). Eighteen of these 55 had a normal ferritin. In summary, NTBI is frequently found in C282Y homozygotes with TS ≥ 50%. Furthermore, C282Y homozygotes in the maintenance phase often have TS ≥ 50% together with a normal ferritin. Therefore, monitoring the TS level during the maintenance phase is recommended as an accessible clinical marker of the presence of NTBI. John Wiley and Sons Inc. 2022-07-27 /pmc/articles/PMC9422009/ /pubmed/36051052 http://dx.doi.org/10.1002/jha2.507 Text en © 2022 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Sickle Cell, Thrombosis, and Benign Haematology Ryan, Eleanor Mulready, Keith Wiegerinck, Erwin Russell, Jennifer Swinkels, Dorine W. Stewart, Stephen NTBI levels in C282Y homozygotes after therapeutic phlebotomy |
title | NTBI levels in C282Y homozygotes after therapeutic phlebotomy |
title_full | NTBI levels in C282Y homozygotes after therapeutic phlebotomy |
title_fullStr | NTBI levels in C282Y homozygotes after therapeutic phlebotomy |
title_full_unstemmed | NTBI levels in C282Y homozygotes after therapeutic phlebotomy |
title_short | NTBI levels in C282Y homozygotes after therapeutic phlebotomy |
title_sort | ntbi levels in c282y homozygotes after therapeutic phlebotomy |
topic | Sickle Cell, Thrombosis, and Benign Haematology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9422009/ https://www.ncbi.nlm.nih.gov/pubmed/36051052 http://dx.doi.org/10.1002/jha2.507 |
work_keys_str_mv | AT ryaneleanor ntbilevelsinc282yhomozygotesaftertherapeuticphlebotomy AT mulreadykeith ntbilevelsinc282yhomozygotesaftertherapeuticphlebotomy AT wiegerinckerwin ntbilevelsinc282yhomozygotesaftertherapeuticphlebotomy AT russelljennifer ntbilevelsinc282yhomozygotesaftertherapeuticphlebotomy AT swinkelsdorinew ntbilevelsinc282yhomozygotesaftertherapeuticphlebotomy AT stewartstephen ntbilevelsinc282yhomozygotesaftertherapeuticphlebotomy |